RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.6%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$696M
AUM Growth
+$696M
(+10%)
Cap. Flow
+$37.9M
Cap. Flow
% of AUM
5.44%
Top 10 Holdings %
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
37
Closed
4
Top Buys
| 1 |
NovoCure
NVCR
|
$21M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$13.8M |
| 3 |
Exelixis
EXEL
|
$10.3M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$7.96M |
| 5 |
Sanofi
SNY
|
$7.67M |
Top Sells
| 1 |
Amgen
AMGN
|
$11.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$10.8M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$8.62M |
| 4 |
Esperion Therapeutics
ESPR
|
$8.33M |
| 5 |
Biogen
BIIB
|
$5.29M |
Sector Composition
| 1 | Healthcare | 92.59% |
| 2 | Financials | 0.93% |
| 3 | Technology | 0.13% |
| 4 | Energy | 0.1% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
AbbVie
ABBV
$374B
| $9.79M | 1.41% |
135,000
+5,000
| +4% | +$363K |
|
27
Merck
MRK
$210B
| $8.97M | 1.29% |
140,000
-20,000
| -13% | -$1.28M |
|
28
Humana
HUM
$37.5B
| $8.42M | 1.21% |
35,000
+3,000
| +9% | +$722K |
|
29
HCA Healthcare
HCA
$95.4B
| $8.26M | 1.19% |
94,707
-10,000
| -10% | -$872K |
|
30
Centene
CNC
$14.8B
| $7.99M | 1.15% |
100,000
+12,407
| +14% | +$991K |
|
31
Alkermes
ALKS
$4.95B
| $7.85M | 1.13% |
135,409
-5,000
| -4% | -$290K |
|
|
WBA
32
DELISTED
Walgreens Boots Alliance
WBA
| $7.83M | 1.12% |
100,000
+55,000
| +122% | +$4.31M |
|
|
33
Sanofi
SNY
$122B
| $7.67M | 1.1% |
+160,000
| New | +$7.67M |
|
|
ELGX
34
DELISTED
Endologix Inc
ELGX
| $7.66M | 1.1% |
1,575,000
-25,000
| -2% | -$122K |
|
35
DexCom
DXCM
$30.9B
| $7.64M | 1.1% |
104,380
+47,480
| +83% | +$3.47M |
|
36
Cigna
CI
$80.2B
| $7.53M | 1.08% |
45,000
-19,000
| -30% | -$3.18M |
|
|
37
Regeneron Pharmaceuticals
REGN
$59.8B
| $7.42M | 1.06% |
15,100
-21,900
| -59% | -$10.8M |
|
38
CVS Health
CVS
$93B
| $6.84M | 0.98% |
85,000
-45,000
| -35% | -$3.62M |
|
|
ADMS
39
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $6.44M | 0.92% |
368,166
+213,166
| +138% | +$3.73M |
|
40
Alnylam Pharmaceuticals
ALNY
$58.6B
| $6.4M | 0.92% |
80,190
-49,810
| -38% | -$3.97M |
|
41
Bristol-Myers Squibb
BMY
$96.7B
| $6.33M | 0.91% |
113,595
-87,405
| -43% | -$4.87M |
|
42
LivaNova
LIVN
$3.09B
| $6.23M | 0.9% |
+101,854
| New | +$6.23M |
|
|
PTLA
43
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.22M | 0.89% |
110,805
-10,000
| -8% | -$562K |
|
|
KITE
44
DELISTED
Kite Pharma, Inc.
KITE
| $6.22M | 0.89% |
60,000
-50,000
| -45% | -$5.18M |
|
45
Universal Health Services
UHS
$11.6B
| $6.1M | 0.88% |
50,000
+15,000
| +43% | +$1.83M |
|
|
46
Amgen
AMGN
$153B
| $6.03M | 0.87% |
35,000
-65,000
| -65% | -$11.2M |
|
|
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
| $5.81M | 0.83% |
220,000
+10,000
| +5% | +$264K |
|
48
Dynavax Technologies
DVAX
$1.19B
| $5.67M | 0.81% |
587,330
-397,366
| -40% | -$3.83M |
|
|
AET
49
DELISTED
Aetna Inc
AET
| $5.62M | 0.81% |
37,000
-15,000
| -29% | -$2.28M |
|
50
Neurocrine Biosciences
NBIX
$13.5B
| $5.52M | 0.79% |
120,000
+35,000
| +41% | +$1.61M |
|